Table 1.
Demographic and Clinicopathological Characteristics of 74 HCC Patients
| Factors | Value | Percent |
|---|---|---|
| Age | 50.5 ± 12.4 | |
| Gender (male/female) | 67/7 | 90.5/9.5 |
| BCLC Stage | ||
| A | 2 | 2.7 |
| B | 34 | 45.9 |
| C | 38 | 51.4 |
| Types of cirrhosis | ||
| Normal | 17 | 23.3 |
| Micronodular | 4 | 5.4 |
| Macronodular | 34 | 45.9 |
| Mixed | 19 | 25.7 |
| TNM stage | ||
| 1 | 32 | 43.2 |
| 2 | 36 | 48.7 |
| 3 | 6 | 8.1 |
| Neoadjuvant Therapy | 0 | 0 |
| Hepatectomy | 74 | 100 |
| Laboratory values | ||
| White blood cell (× 109/L) | 5.48 ± 1.99 | |
| Platelet (× 109/L) | 146 ± 73 | |
| Total bilirubin (umol/L) | 14.6 ± 5.5 | |
| Direct bilirubin (umol/L) | 5.6 ± 2.7 | |
| Albumin (g/L) | 42.6 ± 4.1 | |
| ALT (U/L) | 56.1 ± 40.5 | |
| AST (U/L) | 42.7 ± 21.4 | |
| Glucose (mmol/L) | 5.0 ± 1.0 | |
| CEA (ng/ml) | 4.2 ± 7.9 | |
| CA19-9 (U/ml) | 14.9 ± 8.5 | |
| AFP (ng/ml) | 324.7 ± 425.3 | |
AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, BCLC the Barcelona Clinic Liver Cancer, CA19-9 carbohydrate antigen 19–9, CEA Carcinoembryonic antigen, TNM tumor-node-metastasis